35897-51-9

Basic information

• Product Name: 2-Furancarboxylic acid, 5-benzoyl-
• Synonyms: 5-benzoyl-furan-2-carboxylic acid;5-Benzoylbrenzschleimsaeure;2-Furancarboxylic acid,5-benzoyl
• CAS NO: 35897-51-9
• Molecular Formula: C12H8O4
• Molecular Weight: 216.193
• Mol File: 35897-51-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Furancarboxylic acid, 5-benzoyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarboxylic acid, 5-benzoyl-(35897-51-9)
• EPA Substance Registry System: 2-Furancarboxylic acid, 5-benzoyl-(35897-51-9)

Safety Data

• Hazardous Substances Data: 35897-51-9(Hazardous Substances Data)

Upstream product

• 611-13-2 2-furoic acid methyl ester 
• 98-88-4 benzoyl chloride 
• 58972-21-7 5-Methoxycarbonyl-furan-2-yl phenyl ketone 

Downstream Products

• 1608112-41-9 5-(hydroxy(phenyl)methyl)-N-methyl-N-(3,4,5-trimethoxyphenyl)furan-2-carboxamide 

Relevant articles and documents

N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties

Urea transporters (UTs) have been identified as new targets for diuretics. Functional deletion of UTs led to urea-selective urinary concentrating defects with relative salt sparing. In our previous study, a UT inhibitor with a diarylamide scaffold, which is denoted as 11a, was demonstrated as the first orally available UT inhibitor. However, the oral bioavailability of 11a was only 4.38%, which obstructed its clinical application. In this work, by replacing the nitro group of 11a with an acetyl group, 25a was obtained. Compared with 11a, 25a showed a 10 times stronger inhibitory effect on UT-B (0.14 μM vs. 1.41 μM in rats, and 0.48 μM vs. 5.82 μM in mice) and a much higher inhibition rate on UT-A1. Moreover, the metabolic stability both in vitro and in vivo and the drug-like properties (permeability and solubility) of 25a were obviously improved compared with those of 11a. Moreover, the bioavailability of 25a was 15.18%, which was 3 times higher than that of 11a, thereby resulting in significant enhancement of the diuretic activities in rats and mice. 25a showed excellent potential for development as a promising clinical diuretic candidate for targeting UTs to treat diseases that require long-term usage of diuretics, such as hyponatremia.

Base-mediated decomposition of amide-substituted furfuryl tosylhydrazones: Synthesis and cytotoxic activities of enynyl-ketoamides

Base-mediated decomposition of amide-substituted furfuryl tosylhydrazones afforded practical access to novel multifunctionalized enynyl-ketoamides. In addition, furfuryl tosylhydrazones with stable furan rings underwent an interesting tosyl-group migratio

EP2 RECEPTOR AGONISTS

A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.